Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TOTTORI-HIC study
jRCT1061230070Not yet recruiting
- Start
- Oct 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Open-label, single-arm trial of tofogliflozin in type 2 diabetes mellitus (T2DM), sponsored by None. Primary endpoint: Fasting hepatic insulin clearance at 24 weeks. Planned start Oct 2023; status: not yet recruiting.
02
Drugs
tofogliflozin
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on jRCT1061230070.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT1061230070.